To the Editor: The Heart Outcomes Prevention Evaluation Studyinvestigators (Jan. 20 issue)1 found that the administrationof ramipril to a population of high-risk patients significantlyreduced the rates of myocardial infarction, stroke, and deathfrom cardiovascular causes. However, the data provided in thisstudy raise questions as to whether angiotensin-converting–enzyme(ACE) inhibitors offer substantive clinical benefits over currenttherapeutic standards.
The authors state that "the benefits of ramipril were observedamong patients who were already taking a number of effectivetreatments, such as aspirin, beta-blockers, and lipid-loweringagents, indicating that the inhibition of angiotensin-converting–enzymeoffers an additional approach to . . . [Full Text of this Article]
References
This article has been cited by other articles:
London, G. M., Asmar, R. G., O'Rourke, M. F., Safar, M. E., REASON Project Investigators,
(2004). Mechanism(s) of selective systolic blood pressure reduction after a low-dose combination of perindopril/Indapamide in hypertensive subjects: comparison with atenolol. J Am Coll Cardiol
43: 92-99
[Abstract][Full Text]
Nichols, W. W., Schuler, B., O'Rourke, M. F., Mathew, J., Sleight, P., Lonn, E., Yi, Q., Pogue, J., Bosch, J., Yusuf, S., Johnstone, D., Sussex, B., Probstfield, J.
(2002). Ramipril and Cardiovascular Risk Reduction * Response. Circulation
105
: e194-e195
[Full Text]
Pauca, A. L., O'Rourke, M. F., Kon, N. D.
(2001). Prospective Evaluation of a Method for Estimating Ascending Aortic Pressure From the Radial Artery Pressure Waveform. Hypertension
38: 932-937
[Abstract][Full Text]
Previous
